166 related articles for article (PubMed ID: 36612020)
1. Neuroblastoma Tumor-Associated Mesenchymal Stromal Cells Regulate the Cytolytic Functions of NK Cells.
Di Matteo S; Avanzini MA; Pelizzo G; Calcaterra V; Croce S; Spaggiari GM; Theuer C; Zuccotti G; Moretta L; Pelosi A; Azzarone B
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612020
[TBL] [Abstract][Full Text] [Related]
2. Identification of neuroblastoma cell lines with uncommon TAZ
Canzonetta C; Pelosi A; Di Matteo S; Veneziani I; Tumino N; Vacca P; Munari E; Pezzullo M; Theuer C; De Vito R; Pistoia V; Tomao L; Locatelli F; Moretta L; Caruana I; Azzarone B
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452207
[TBL] [Abstract][Full Text] [Related]
3. Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells.
Di Matteo S; Bilotta MT; Pelosi A; Haas D; Theinert T; Weber G; Schlegel PG; Berg M; Moretta L; Maggi E; Azzarone B; Vacca P; Tumino N; Caruana I
Front Immunol; 2024; 15():1382931. PubMed ID: 38736882
[TBL] [Abstract][Full Text] [Related]
4. Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells.
Pelizzo G; Veschi V; Mantelli M; Croce S; Di Benedetto V; D'Angelo P; Maltese A; Catenacci L; Apuzzo T; Scavo E; Moretta A; Todaro M; Stassi G; Avanzini MA; Calcaterra V
BMC Cancer; 2018 Nov; 18(1):1176. PubMed ID: 30482160
[TBL] [Abstract][Full Text] [Related]
5. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
6. Fibroblasts and macrophages cooperate to create a pro-tumorigenic and immune resistant environment via activation of TGF-β/IL-6 pathway in neuroblastoma.
Louault K; Porras T; Lee MH; Muthugounder S; Kennedy RJ; Blavier L; Sarte E; Fernandez GE; Yang F; Pawel BR; Shimada H; Asgharzadeh S; DeClerck YA
Oncoimmunology; 2022; 11(1):2146860. PubMed ID: 36479153
[TBL] [Abstract][Full Text] [Related]
7. Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity.
Johann PD; Vaegler M; Gieseke F; Mang P; Armeanu-Ebinger S; Kluba T; Handgretinger R; Müller I
BMC Cancer; 2010 Sep; 10():501. PubMed ID: 20858262
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
9. Human bone marrow stromal cells and skin fibroblasts inhibit natural killer cell proliferation and cytotoxic activity.
Pradier A; Passweg J; Villard J; Kindler V
Cell Transplant; 2011; 20(5):681-91. PubMed ID: 21054933
[TBL] [Abstract][Full Text] [Related]
10. Efficient Killing of High Risk Neuroblastoma Using Natural Killer Cells Activated by Plasmacytoid Dendritic Cells.
Cordeau M; Belounis A; Lelaidier M; Cordeiro P; Sartelet H; Herblot S; Duval M
PLoS One; 2016; 11(10):e0164401. PubMed ID: 27716850
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
[TBL] [Abstract][Full Text] [Related]
12. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
[TBL] [Abstract][Full Text] [Related]
13. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.
Esser R; Müller T; Stefes D; Kloess S; Seidel D; Gillies SD; Aperlo-Iffland C; Huston JS; Uherek C; Schönfeld K; Tonn T; Huebener N; Lode HN; Koehl U; Wels WS
J Cell Mol Med; 2012 Mar; 16(3):569-81. PubMed ID: 21595822
[TBL] [Abstract][Full Text] [Related]
14. NK Cell-derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells.
Shoae-Hassani A; Hamidieh AA; Behfar M; Mohseni R; Mortazavi-Tabatabaei SA; Asgharzadeh S
J Immunother; 2017 Sep; 40(7):265-276. PubMed ID: 28622272
[TBL] [Abstract][Full Text] [Related]
15. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their
Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
Front Immunol; 2019; 10():2816. PubMed ID: 31849984
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches.
Bottino C; Dondero A; Bellora F; Moretta L; Locatelli F; Pistoia V; Moretta A; Castriconi R
Front Immunol; 2014; 5():56. PubMed ID: 24575100
[TBL] [Abstract][Full Text] [Related]
17. Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
Veneziani I; Brandetti E; Ognibene M; Pezzolo A; Pistoia V; Cifaldi L
J Immunol Res; 2018; 2018():4972410. PubMed ID: 29805983
[TBL] [Abstract][Full Text] [Related]
18. MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.
Brandetti E; Veneziani I; Melaiu O; Pezzolo A; Castellano A; Boldrini R; Ferretti E; Fruci D; Moretta L; Pistoia V; Locatelli F; Cifaldi L
Oncoimmunology; 2017; 6(6):e1316439. PubMed ID: 28680748
[TBL] [Abstract][Full Text] [Related]
19. Differential Immunomodulatory Effects of Human Bone Marrow-Derived Mesenchymal Stromal Cells on Natural Killer Cells.
Hu CD; Kosaka Y; Marcus P; Rashedi I; Keating A
Stem Cells Dev; 2019 Jul; 28(14):933-943. PubMed ID: 31122145
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the interaction between human decidua parietalis mesenchymal stem/stromal cells and natural killer cells.
Abumaree MH; Bahattab E; Alsadoun A; Al Dosaimani A; Abomaray FM; Khatlani T; Kalionis B; El-Muzaini MF; Alawad AO; AlAskar AS
Stem Cell Res Ther; 2018 Apr; 9(1):102. PubMed ID: 29650045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
